A synthetic growth hormone-releasing hormone (GHRH) analog engineered with 4 amino acid substitutions to resist enzyme cleavage.
~30 minutes (no DAC) / 6-8 days (with DAC)
GHRH Receptor
C152H252N44O42
Administered primarily via subcutaneous injection, commonly co-administered with Ipamorelin.
Small or observational human data; warrants clinical caution.
Animal (rodent) and in-vitro cellular assays. Does NOT prove human efficacy.
Formal regulatory oversight and verified clinical development phase.
Evidence classification for CJC-1295: Human clinical data is strictly differentiated from non-human animal and in-vitro laboratory assays.
C152H252N44O42
Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2
CJC-1295 is an analog of GHRH (1-29) developed to extend the metabolic stability of native GHRH. Available as Modified GRF 1-29 (without DAC, short acting) or CJC-1295 with DAC (Drug Affinity Complex, long acting). It preserves natural pulsatile GH release when combined with ghrelin mimetics.
Binds specifically to the pituitary GHRH receptor, stimulating the transcription and secretion of endogenous growth hormone in a physiological pulsatile manner without desensitizing receptors.
Peer-reviewed publications, clinical trials, and preclinical research investigating CJC-1295.
Documented literature dosing intervals and published clinical trial protocols.
Frequency: Before bedtime (5 on / 2 off)
“Commonly co-administered with equal mcg dose of Ipamorelin to leverage dual receptor synergy on an empty stomach.”
Biological delivery routes and standardized laboratory reconstitution principles.
Administered primarily via subcutaneous injection, commonly co-administered with Ipamorelin.
Lyophilized peptides must be reconstituted using sterile bacteriostatic water (0.9% benzyl alcohol) and maintained strictly refrigerated between 2°C - 8°C (36°F - 46°F), shielded from light.
View Full Preparation ProtocolCompiled from peer-reviewed biomedical literature, public clinical trial registries, and recognized reference catalog databases.
Pharmacological profiles, receptor targets, and clinical data are verified against primary registries:
Community research topics, peptide nomenclature, and aliases are cross-referenced with public catalogs:
This topic was identified through research of publicly available peptide resources and peer-reviewed literature. Peptide Health Digest provides independent scientific explanations and does not endorse commercial distribution.
